Rabeprazole and Acute coronary syndrome - a phase IV clinical study of FDA data
Acute coronary syndrome is found among people who take Rabeprazole, especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years.
The phase IV clinical study analyzes which people take Rabeprazole and have Acute coronary syndrome. It is created by eHealthMe based on reports of 25,697 people who have side effects when taking Rabeprazole from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
25,697 people reported to have side effects when taking Rabeprazole.
Among them, 31 people (0.12%) have Acute coronary syndrome.
What is Rabeprazole?
Rabeprazole has active ingredients of rabeprazole sodium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 26,157 Rabeprazole users for its effectiveness, alternative drugs and more.
What is Acute coronary syndrome?
Acute coronary syndrome (acute chest pain and other symptoms that happen because the heart does not get blood) is found to be associated with 1,429 drugs and 920 conditions by eHealthMe.
Number of Rabeprazole and Acute coronary syndrome reports submitted per year:
Time on Rabeprazole when people have Acute coronary syndrome *:
- < 1 month: 33.33 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 66.67 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Acute coronary syndrome when taking Rabeprazole *:
- female: 31.03 %
- male: 68.97 %
Age of people who have Acute coronary syndrome when taking Rabeprazole *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 7.14 %
- 50-59: 7.14 %
- 60+: 85.71 %
Common drugs people take besides Rabeprazole *:
- Plavix: 15 people, 48.39%
- Ramipril: 14 people, 45.16%
- Zantac: 14 people, 45.16%
- Pantoprazole: 13 people, 41.94%
- Miralax: 13 people, 41.94%
- Prilosec: 13 people, 41.94%
- Nitroglycerin: 12 people, 38.71%
- Oxybutynin: 12 people, 38.71%
- Zometa: 11 people, 35.48%
- Omeprazole: 11 people, 35.48%
Common side effects people have besides Acute coronary syndrome *:
- Breathing Difficulty: 15 people, 48.39%
- Anaemia (lack of blood): 14 people, 45.16%
- Thrombocytopenia (decrease of platelets in blood): 14 people, 45.16%
- Coronary Heart Disease (narrowing or blockage of the coronary arteries): 13 people, 41.94%
- Heart Attack: 12 people, 38.71%
- Diarrhea: 12 people, 38.71%
- Fatigue (feeling of tiredness): 12 people, 38.71%
- Weakness: 12 people, 38.71%
- Swallowing Difficulty: 12 people, 38.71%
- Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 12 people, 38.71%
Common conditions people have *:
- Pain: 14 people, 45.16%
- High Blood Pressure: 13 people, 41.94%
- Stress And Anxiety: 11 people, 35.48%
- Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 11 people, 35.48%
- Multiple Myeloma (cancer of the plasma cells): 11 people, 35.48%
- Metastases To Bone (cancer spreads to bone): 11 people, 35.48%
- Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough): 11 people, 35.48%
- Insomnia (sleeplessness): 9 people, 29.03%
- Essential Thrombocythaemia (chronic blood cancer): 3 people, 9.68%
- Weakness: 2 people, 6.45%
* Approximation only. Some reports may have incomplete information.
Do you take Rabeprazole and have Acute coronary syndrome?Check whether Acute coronary syndrome is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Acute coronary syndrome and when was it recovered:
Expand to all the drugs that have ingredients of rabeprazole sodium:
Alternative drugs to, pros and cons of Rabeprazole:
- Rabeprazole (26,157 reports)
Common Rabeprazole side effects:
- Drug ineffective: 1,886 reports
- Pain: 1,687 reports
- Diarrhea: 1,657 reports
- Fatigue (feeling of tiredness): 1,561 reports
- Pneumonia: 1,550 reports
- Joint pain: 1,463 reports
- Breathing difficulty: 1,457 reports
- Malaise (a feeling of general discomfort or uneasiness): 1,348 reports
- High blood pressure: 1,344 reports
Browse all side effects of Rabeprazole:a b c d e f g h i j k l m n o p q r s t u v w x y z
Acute coronary syndrome treatments and more:
- Acute coronary syndrome (20,153 reports)
COVID vaccines that are related to Acute coronary syndrome:
- Acute coronary syndrome in Moderna COVID Vaccine
- Acute coronary syndrome in Pfizer BioNTech Covid Vaccine
- Acute coronary syndrome in Johnson and Johnson Covid Vaccine
Common drugs associated with Acute coronary syndrome:
- Avandia: 1,225 reports
- Aspirin: 1,091 reports
- Vioxx: 694 reports
- Metformin: 600 reports
- Plavix: 586 reports
- Clopidogrel: 419 reports
- Furosemide: 400 reports
- Lipitor: 386 reports
- Ramipril: 383 reports
- Simvastatin: 361 reports
All the drugs that are associated with Acute coronary syndrome:
- Acute coronary syndrome (1,429 drugs)
Common conditions associated with Acute coronary syndrome:
- Diabetes: 1,120 reports
- High blood pressure: 764 reports
- Rheumatoid arthritis: 358 reports
- Type 2 diabetes: 327 reports
- Atrial fibrillation/flutter: 288 reports
All the conditions that are associated with Acute coronary syndrome:
- Acute coronary syndrome (920 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on rabeprazole sodium (the active ingredients of Rabeprazole) and Rabeprazole (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Etodolac and Effexor Xr drug interaction - 7 seconds ago
- Oedema and Lymphopenia - 35 seconds ago
- Norlutate and Depression - 44 seconds ago
- Atenolol and Drug Toxicity - a minute ago
- Univasc and Appendicitis - a minute ago
- Divalproex and Hepatic Cirrhosis - a minute ago
- Amoxicillin and Tinnitus - 2 minutes ago
- Tamiflu and Amylase Increased - 2 minutes ago
- Levaquin and Seizures - 2 minutes ago
- Schizoaffective Disorder Bipolar Type and Abdominal Pain - 2 minutes ago